Skip to main content
Caplight Logo









ViroCell Biologics

ViroCell Biologics

Private
LondonHealthcare & Life Scienceshttps://www.virocell.com/

Last Round

Convertible Debt

Aug 14, 2024

Company Overview

ViroCell Biologics is a biotechnology company that operates as a contract development and manufacturing organization (CDMO) focused on the design, optimization, and GMP manufacturing of lentiviral and retroviral vectors for cell and gene therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Pharma Supply Chain, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

contract development and manufacturing organizationCDMOviral vector manufacturingretroviral vectorlentiviral vectorcell and gene therapyGMP manufacturinggene therapy CDMOCGTclinical trial manufacturingprocess developmentviral vector designCAR-TTCR therapyregulatory support

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ViroCell Biologics Comparables

Compare ViroCell Biologics with similar companies based on industry and business-model similarity.

ViroCell Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vector BioMed, Inc.
93%
Genezen
89%
VIVEbiotech
89%

ViroCell Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtAug 14, 2024
SeedApr 28, 2021

Key People

Founding team and executive leadership

Farzin Farzaneh

Chief Scientific Officer, Co-Founder

Founding Team

John W. Hadden

Chief Executive Officer & Co-Founder

Founding Team

Brian Collins

Chief Financial Officer

Executive Team

ViroCell Biologics Investors

Notable investors and investment history

ViroCell Biologics investors
InvestorRounds
Disruptive CapitalSeed
Truell Conservation FoundationSeed
First Light Asset ManagementConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 2, 2025

    Monthly visitors increased 536% MoM, reaching 8.9K.

  • Mar 24, 2025

    Monthly visitors increased 42% MoM.

ViroCell Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ViroCell Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ViroCell Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range59
Year Founded2020
Last FundingAug 14, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?